English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We examined which regimen of triweekly or biweekly docetaxel in combination with irinotecan demonstrates superiority of the antitumor activity and toxicity in patients with refractory or relapsed advanced non-small-cell lung cancer (NSCLC). Patients with previously treated NSCLC of stage III or IV were eligible if they had a performance status of 2 or less, and were 75 years or younger. Patients were treated every 3 weeks with docetaxel (50 mg / m2 on day 2) plus irinotecan (50 mg / m2 on days 1 and 8) or every 4 weeks with docetaxel (33 mg / m2 on days 2 and 16) plus irinotecan (50 mg / m2 on days 1 and 15). Fifty patients were enrolled. Patient characteristics were not significantly different between the triweekly and biweekly arms. The overall response rates were 6.7 % and 14.3 % , times to progression were 2 months and 3 months, median survival times were 5 months and 8 months, and 1-year survival rates were 20% and 30% in the triweekly and biweekly arms, respectively. There were no differences in response rates, TTP, and survival between arms. In the triweekly arm, grade-3 or -4 leukopenia and diarrhea occurred more frequently than in the biweekly arm. In both arms, 2 patients had grade 3 to 4 drug-induced interstitial pneumonia but recovered after receiving steroid therapy. There were no treatment-related deaths. The biweekly arm demonstrated similar efficacy and better tolerability than the triweekly arm and can be recommended as an alternative treatment option in patients with refractory or relapsed NSCLC.

Comparison of Biweekly and Triweekly Therapy with Docetaxel and Irinotecan for Refractory or Relapsed Advanced Non-small-cell Lung cancer